Clinical Trial

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Study acronym: LNCB74-01
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-13; most recent amendment 2025-12-08.
Trial Details
NCT Number NCT06774963
Lead Sponsor NextCure, Inc.
Collaborators: LigaChem Biosciences, Inc.
Conditions Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
Enrollment 145 participants
Start Date 2025-01-07
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-16